Recently, the Wuhan Institute of virology / biosafety research center of Chinese Academy of Sciences and the National Center of emergency prevention and control drug engineering and technology of Military Medical Research Institute of Chinese Academy of military sciences have carried out joint research, making important progress in inhibiting drug screening of 2019 new coronavirus (2019 ncov). Relevant research results were published in the international well-known academic journal Cell Research with independent intellectual property rights in China, entitled remdesivir and chloroquine phosphate can effectively inhibit the new coronavirus (2019 ncov) invitro.
This study shows that on veroe6 cells, the half effective concentration of remidesivir (gs-5734) to 2019-ncov is EC50 = 0.77um (micromol / L), the selection index Si is greater than 129; the EC50 = 1.13um, Si is greater than 88 of chloroquine phosphate, indicating that the above two drugs can effectively inhibit 2019-ncov infection at the cellular level, and their effect on human body remains to be clinically tested Card.
Remdesivir (gs-5734) is a nucleoside analogue. At present, phase II and phase III clinical studies on the treatment of Ebola haemorrhagic fever have been carried out in DRC. Chloroquine phosphate has been used in the treatment of malaria since the 1940s, and then in the treatment of rheumatoid arthritis. The preliminary results of the above two drugs effectively inhibiting the infection of new coronavirus 2019 at the cellular level have been reported to the relevant departments of the state, provinces and cities in various forms. In order to serve the epidemic prevention and control, the two parties jointly declare that: among the above drugs with anti-2019 new coronavirus effect, we do not apply for related patents for the drug chloroquine phosphate that has been listed in China and can fully realize independent supply, so as to encourage the enthusiasm of relevant enterprises to participate in the epidemic prevention and control; for the drug that has not been listed in China and has intellectual property barriers Ridceway, in accordance with international practice and from the perspective of protecting national interests, filed a Chinese invention patent (anti-2019 new coronavirus use) on January 21, and will enter major countries in the world through PCT (patent cooperation agreement). If the relevant foreign enterprises intend to contribute to the prevention and control of epidemic in China, we both agree that we will not require the implementation of the rights claimed in the patent for the time being, and we hope to cooperate with foreign pharmaceutical companies to make a modest contribution to the prevention and control of epidemic.
Wang Manli, researcher of Wuhan Institute of Virology, Cao Ruiyuan, associate researcher of National Center for emergency drug engineering and technology of Military Medical Research Institute, Zhang leipeng, associate researcher of Wuhan Institute of Virology, Yang Xinglou, associate first author of the paper, Xiao Gengfu, researcher of Wuhan Institute of Virology, Zhong Wu, researcher of National Center for emergency drug engineering and technology of Military Medical Research Institute Hu Zhihong, a researcher of hanvirus Institute, is the co-author, Liu Jia, Xu Mingyue, Shi Zhengli, etc. Wang Xi, Wu Yan, Shang Weijuan, Zhang Huanyu, Li Yufeng, Hu Hengrui, Jiang Xiaming and sun yuan from Wuhan Institute of Virology participated in the project. The work was strongly supported by the national virus resource bank and Wuhan National biosafety laboratory, and supported by the national science and technology major project of major new drug creation (2018zx09711003), the National Natural Science Foundation innovation group project (31621061) and the 2019 new pneumonia emergency research project in Hubei Province.